Description
A dopamine D3 receptor partial agonist; selectively binds to the dopamine D3 over the D2, D1, and D4 receptors (Kis = 0.92, 61, 3,000, and 300 nM, respectively, for the recombinant human receptors); selective over α1- and α2-adrenergic receptors (Kis = 60 and 83 nM, respectively) and the serotonin receptor subtypes 5-HT1A and 5-HT7 (Kis = 84 and 345 nM, respectively), as well as muscarinic, histamine, and opioid receptors (Kis = >1 µM for all); increases mitogenesis in NG 108-15 cells with a maximum efficacy of 55%; acts as a dopamine D3 receptor antagonist in a [35S]GTPγS binding assay, inhibiting the effect of dopamine (IC50 = 416.87 nM); reduces cocaine-seeking behavior, but has no reinforcing properties itself, in rats trained to self-administer cocaine at 0.5 and 1 mg/kg
Formal name: N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-naphthalenecarboxamide, monohydrochloride
Synonyms:
Molecular weight: 454
CAS: 314776-92-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research
